Natera (NTRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on February 28. Analyst Puneet Souda from Leerink Partners maintained a Buy rating on the stock and has a $200.00 price target.
Puneet Souda has given his Buy rating due to a combination of factors that highlight Natera’s strong market position and growth potential. The company has shown impressive performance in the minimal residual disease (MRD) market, which is valued at approximately $20 billion. Natera’s recent financial results exceeded expectations, with significant revenue growth driven by its Signatera product. The company’s guidance for 2025 also indicates continued robust growth, supported by anticipated gross margin expansion.
Furthermore, Natera has several upcoming catalysts that could further enhance its market position. These include potential updates to clinical guidelines, new product launches, and results from ongoing clinical trials. The company’s leadership in the MRD market is reinforced by its extensive peer-reviewed publications and recent coverage expansions. With these growth drivers and strategic initiatives, Puneet Souda believes Natera is well-positioned to meet and potentially exceed investor expectations, justifying the Buy rating.
According to TipRanks, Souda is an analyst with an average return of -13.0% and a 28.08% success rate. Souda covers the Healthcare sector, focusing on stocks such as Natera, Castle Biosciences, and Hologic.
In another report released on February 28, Barclays also maintained a Buy rating on the stock with a $200.00 price target.